Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/2023-509341-12-00
2023-509341-12-00RecruitingPhase 2

AN OPEN LABEL, RANDOMISED, CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY OF ENDOBRONCHIAL ADMINISTRATION OF ALLOGENEIC MESENCHYMAL STROMAL CELLS IN PATIENTS WITH LUNG TRANSPLANT CHRONIC REJECTION: Study ENDOSC-CLAD

Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda1 site in 1 country12 target enrollmentStarted: November 14, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
12
Locations
1
Primary Endpoint
Incidence of early onset (24h) adverse events following MSCs administration: desaturation, hypotension, radiological infiltrates, fever or changes in oxygen therapy requirements.
Study OverviewEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To assess the safety of endobronchial administration of allogeneic MSCs in patients with BO.

Eligibility Criteria

Ages
18 years to 64 years (18-64 Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients should have signed written informed consent.
  • •Adult patients ≥18 years of age at the time of enrolment
  • •Patients recipients of a uni or bipulmonary transplant
  • •An established diagnosis of BOS ≧ 0p (FEV1≤90% and / or FEF 25-75% ≤ of the baseline value with no other justifying cause) in the last 6 months.

Exclusion Criteria

  • •History of lobar transplantation
  • •Performance status 3 or 4 (confined to bed or chair for more than 50% of waking hours, able only to perform some self-care activities)
  • •Estimated survival less than 3 months.
  • •Known hypersensitivity to components used in the production of allogeneic MSCs.
  • •Any circumstance that, in the opinion of the investigator, compromises the patient's ability to participate in the clinical trial.
  • •History of heart-lung transplantation
  • •Active infection at the time of inclusion.
  • •Active Acute Rejection not treated at the time of inclusion.
  • •Oncological history (except cutaneous basal cell or carcinoma in situ)
  • •Systemic autoimmune diseases.
  • •Active HIV / HBV / HCV infection (confirmed by serology or PCR)
  • •Proximal airway stenosis
  • •Pregnant women, female subjects planning or willing to get pregnant during the duration of the study will not be able to enroll.

Outcomes

Primary Outcomes

Incidence of early onset (24h) adverse events following MSCs administration: desaturation, hypotension, radiological infiltrates, fever or changes in oxygen therapy requirements.

Incidence of early onset (24h) adverse events following MSCs administration: desaturation, hypotension, radiological infiltrates, fever or changes in oxygen therapy requirements.

Incidence of adverse events of special interest since randomization: lower respiratory tract infections, acute rejection (as defined by the presence of A1-A4 o B1R, B2R in biopsy), BO worsening (as measured by >10% decline in FEV1 from baseline).

Incidence of adverse events of special interest since randomization: lower respiratory tract infections, acute rejection (as defined by the presence of A1-A4 o B1R, B2R in biopsy), BO worsening (as measured by >10% decline in FEV1 from baseline).

Secondary Outcomes

  • Mean changes in FEV1 at 12-month from baseline.
  • Proportion of patients with >10% decrease in FEV1 from baseline.
  • Time to a >10% decrease in FEV1 from baseline.
  • Proportion of patients progressing to grade 3 BO (as defined by a FEV1 below 50% from best value post-transplant).
  • Mean changes in FVC from baseline to 12-month
  • All-cause mortality rate
  • Re-transplant or CLAD-related mortality rate.
  • Rate of acute rejection (as defined by the presence of A1-A4 o B1R, B2R in biopsy) at any time during the 12-month follow up period.
  • Incidence of presence of specific antibodies against donor HLA.
  • CLAD progression, as defined by > 10% decline in FEV1 in two consecutive time-points
  • Mean changes in the mMRC Scale at 12-month.
  • Total hospitalization days during 12-month follow-up period.
  • Proportion of patients requiring ambulatory oxygen therapy.

Investigators

Sponsor Class
Patient organisation/association
Responsible Party
Principal Investigator
Principal Investigator

David Gómez de Antonio

Scientific

Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Phase 2
Phase I/II randomized clinical trial of allogeneic adipose tissue-derived mesenchymal stromal cells systemic infusion in severe systemic sclerosis MSC-AT-SScSystemic sclerosis
2023-505977-34-00Assistance Publique Hopitaux De Paris18
Recruiting
Phase 2
Inhalation therapy in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trialBronchiectasis
2023-509277-22-00Philipps-Universitaet Marburg66
Recruiting
Phase 3
Trial comparing intra-discal allogeneic adult BM-MSC therapy and sham-treated controls in subjects with chronic low back pain due to lumbar degenerative disc disease unresponsive to conventional therapyDegenerative Disc Disease
2023-510000-45-00University Hospital Of Montpellier11
Recruiting
Phase 4
PHARMACOLOGICAL STRATEGIES OF INHALED ANTIBIOTHERAPY IN BRONCHIECTASIS WITH CHRONIC BRONCHIAL INFECTION: BRONCHIPHARMA STUDY.
2023-510220-72-00Consorci Mar Parc De Salut De Barcelona75
Recruiting
Phase 2
A study to test how well BI 3720931 is tolerated and whether it improves lung function in people with cystic fibrosis (LenticlairTM 1)Cystic fibrosis
2023-503281-23-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.12